Overview

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

Status:
Not yet recruiting

Trial end date:
2023-05-13

Target enrollment:

Participant gender:

Summary

This study is a multi-center, randomized, open-label, double-blind, positive-controlled phase II clinical study evaluating the efficacy and safety of different doses of SHR2285 tablets vs. enoxaparin for the prevention of postoperative venous thromboembolism in patients undergoing elective unilateral total knee arthroplasty.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Treatments:

Enoxaparin